UBS upgraded British American Tobacco from Neutral to Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/30/2025 | Buy | BofA Securities | |
| 1/27/2025 | Neutral → Buy | UBS | |
| 10/3/2024 | $33.00 | Overweight → Underweight | Morgan Stanley |
| 1/23/2024 | Neutral | UBS | |
| 11/1/2023 | $38.00 | Overweight | Morgan Stanley |
| 9/25/2023 | Buy | Citigroup | |
| 9/1/2023 | Buy → Hold | Argus | |
| 3/13/2023 | Overweight → Neutral | JP Morgan |
3 - British American Tobacco p.l.c. (0001303523) (Reporting)
BofA Securities resumed coverage of British American Tobacco with a rating of Buy
UBS upgraded British American Tobacco from Neutral to Buy
Morgan Stanley downgraded British American Tobacco from Overweight to Underweight and set a new price target of $33.00
LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla
Organigram and BAT deepen partnership through C$124.6 million investment with 38.7 million shares to be issued over three tranches Organigram to use C$83.1 million of the investment to create "Jupiter," a strategic investment pool designed to expand Organigram's geographic footprint and capitalize on emerging growth opportunities C$41.5 million of the investment will be used for general corporate purposes Investment enhances strategic Product Development Collaboration between BAT and Organigram, which focuses on cutting-edge R&D and product innovation BAT to increase voting Common Share ownership position to 30% and overall equity interest to 45% (including non-voting Class A P